LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SXTC
China SXT Pharmaceuticals, Inc.
There isn't enough reported data to score SXTC yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SXTC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
SXTC's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SXTC PE Valuation
SXTC has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SXTC Forward outlook
There aren't enough analyst estimates for SXTC to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SXTC in the latest year-over-year earnings comparison.
SXTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2019 | $1,440,000,000.00 | +6592401% |
SXTC has swung to a loss: it lost $258,864,000.00 per share over the past year, after a profit the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SXTC in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
SXTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $511.5K | -44% |
| Q3 2025 | $626.6K | -24% |
| Q1 2025 | $911.4K | -7.8% |
| Q3 2024 | $829.5K | -12% |
| Q1 2024 | $988.9K | +30% |
| Q3 2023 | $939.6K | -22% |
| Q1 2023 | $763.4K | -52% |
| Q3 2022 | $1.2M | +18% |
SXTC's revenue has slid since its 2019 peak: $511,482 last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -153% | -844 points |
| Q3 2025 | -1012% | -17 points |
| Q1 2025 | -224% | +360 points |
| Q3 2024 | -77% | +18 points |
| Q1 2024 | 691% | +837 points |
| Q3 2023 | -995% | -714 points |
| Q1 2023 | -584% | -217 points |
| Q3 2022 | -95% | -125 points |
SXTC's operating margin was −153% last quarter, down 844 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
SXTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2022 | -$569.2K | -$235.8K |
| Q1 2022 | $540.8K | +$1.6M |
| Q3 2021 | -$333.5K | +$5K |
| Q1 2021 | -$1.1M | -136% |
| Q3 2020 | -$338.4K | +$1.8M |
| Q1 2020 | $3M | +$3.2M |
| Q1 2019 | -$296.6K | -126% |
| Q1 2018 | $1.2M | +2543% |
SXTC has the edge over LLY in the latest year-over-year cash flow comparison.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SXTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -85% | -88 shares |
| Quarter | Spent |
|---|---|
| Q1 2018 | — |
| Q4 2017 | — |
| Q3 2017 | — |
| Q2 2017 | — |
| Q1 2017 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SXTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -2.8x | Net Cash |
| Q3 2020 | -24.2x | Net Cash |
| Q1 2019 | -4.7x | Net Cash |
| Q1 2018 | -0.1x | Net Cash |
| Q4 2017 | 0.1x | Very low |
SXTC has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SXTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 0.0 | Oversold |
SXTC's weekly RSI is 26 (oversold) and its Stochastic is 0 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SXTC PE vs Healthcare Sector
| Metric | SXTC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SXTC has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SXTC on trend strength, trading above more of its moving averages.
SXTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $66.5 | 96% below |
| 20 week MA | $3,168.2 | 100% below |
| 50 week MA | $201,104.1 | 100% below |
| 100 week MA | $1,416,712.0 | 100% below |
| 200 week MA | $16,515,528.3 | 100% below |
SXTC is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SXTC on returns for 2026, with the stronger performance.
SXTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14,687,808,000.0 | $6,504,960,000.0 | -56% |
| 2021 | $6,504,960,000.0 | $2,753,856,000.0 | -58% |
| 2022 | $2,753,856,000.0 | $124,800,000.0 | -95% |
| 2023 | $124,800,000.0 | $38,112,000.0 | -69% |
| 2024 | $38,112,000.0 | $4,012,800.0 | -89% |
| 2025 | $4,012,800.0 | $1,812,000.0 | -55% |
| 2026 YTD | $1,812,000.0 | $2.73 | -100% |
SXTC has finished every year since 2020 lower, and it's down 100% so far in 2026.